<!doctype html><html lang="zh-hans"><head><meta charset="utf-8"><meta name="viewport" content="width=device-width, initial-scale=1, shrink-to-fit=no"><title>冠状病毒变种：它们的作用以及您应该如何担心 Coronavirus variants: What they do and how worried you should be</title><link rel="stylesheet" href="https://stackpath.bootstrapcdn.com/bootstrap/4.3.1/css/bootstrap.min.css" integrity="sha384-ggOyR0iXCbMQv3Xipma34MD+dH/1fQ784/j6cY/iJTQUOhcWr7x9JvoRxT2MZw1T" crossorigin="anonymous"><link rel="stylesheet" href="/img/css.css?random="><link data-rh="true" rel="icon" href="/img/favicon.ico"/><script data-ad-client="ca-pub-6067137220025946" async src="https://pagead2.googlesyndication.com/pagead/js/adsbygoogle.js"></script><script type="text/javascript" src="https://platform-api.sharethis.com/js/sharethis.js#property=5effb96910009800120b8d4d&product=inline-share-buttons" async="async"></script>
<script>var _hmt = _hmt || [];(function() {var hm = document.createElement("script");hm.src = "https://hm.baidu.com/hm.js?03c1a0f31299b4a2fbb83c34d6beaac9";var s = document.getElementsByTagName("script")[0]; s.parentNode.insertBefore(hm, s);})();</script></head><body><div id="my_header"><div class="container"><nav class="navbar navbar-expand-lg"><a class="navbar-brand" href="/"><img alt="diglog" src="/img/logo.v1.gif" class="rounded-sm"></a><button class="navbar-toggler" type="button" data-toggle="collapse" data-target="#navbarNavAltMarkup" aria-controls="navbarNavAltMarkup" aria-expanded="false" aria-label="Toggle navigation"><span class="navbar-toggler-icon"></span></button><div class="collapse navbar-collapse" id="navbarNavAltMarkup"><div class="navbar-nav"></div></div></nav></div></div><div class="container"><div id="my_content"><h1 class="page_narrow">Coronavirus variants: What they do and how worried you should be<br/>冠状病毒变种：它们的作用以及您应该如何担心 </h1><div class="row"><div class="col-lg-12 col-12"><div class="my_story_list_item shadow p-3 mb-5 bg-white rounded"><div class="story_page_pub_time page_narrow">2021-01-29 08:07:00</div><div class="story_img_container"><a href="http://img2.diglog.com/img/2021/1/cc7572ab9990fdf76e032b6f1611e7f7.jpg"><img src="http://img2.diglog.com/img/2021/1/cc7572ab9990fdf76e032b6f1611e7f7.jpg" class="img-fluid my_story_img" onerror="this.style.display='none'"></a></div><div class="page_narrow text-break page_content"><p>Ever since the novel coronavirus, SARS-CoV-2, began jumping from human to human, it’s been mutating. The molecular machinery the virus uses to read and make copies of its genetic code isn’t great at proofreading; minor typos made in the copying process can go uncorrected. Each time the virus lands in a new human victim, it infects a cell and makes an army of clones, some carrying genetic errors. Those error-bearing clones then continue on, infecting more cells, more people. Each cycle, each infection offers more opportunity for errors. And, over time, those errors, those mutations, accumulate.</p><p>自从新型冠状病毒SARS-CoV-2开始在人与人之间跳跃以来，它一直在变异。病毒用于读取和复制其遗传密码的分子机制在校对方面并不出色。复制过程中出现的轻微错别字可能会更正。病毒每次落入新的人类受害者时，都会感染细胞并产生大量克隆，其中一些克隆带有遗传错误。这些带有错误的克隆然后继续传播，感染更多的细胞，更多的人。每个周期，每种感染都为错误提供了更多机会。而且，随着时间的流逝，那些错误和那些突变会累积起来。</p><p> Some of these changes are meaningless. Some are lost in the frenetic viral manufacturing. But some become permanent fixtures, passed on from virus to virus, human to human. Maybe it happens by chance; maybe it’s because the change helps the virus survive in some small way. But in aggregate, viral strains carrying one notable mutation can start carrying others. Collections of notable mutations start popping up in viral lineages, and sometimes they seem to have an edge over their relatives. That’s when these distinct viruses—these variants—get concerning.</p><p> 其中一些变化是没有意义的。在狂热的病毒制造中，有些人迷失了。但是有些变成了永久性的固定装置，从一种病毒传到另一种病毒，从人传到人。也许它是偶然发生的。也许是因为这种变化有助于病毒以较小的方式存活。但是总的来说，携带一种显着突变的病毒株可以开始携带其他突变。显着突变的集合开始出现在病毒谱系中，有时它们似乎比其亲属更具优势。到那时，这些独特的病毒（这些变体）就会引起关注。</p><p> Scientists around the world have been closely tracking mutations and variants since the pandemic began, watching some rise and fall without much ado. But in recent months, they have become disquieted by at least three variants. These variants of concern, or VOCs, have raised critical questions—and alarm—over whether they can spread more easily than previous viral varieties, whether they can evade therapies and vaccines, or even whether they’re deadlier.</p><p> 自大流行开始以来，世界各地的科学家就一直密切跟踪突变和变异，看着它们的兴衰没有多大的努力。但近几个月来，它们至少被三种变体所困扰。这些令人关注的变种或VOC引发了严峻的问题，并引起了人们的警惕，即它们是否比以前的病毒变种更容易传播，它们是否可以逃避疗法和疫苗，甚至是否更致命。</p><p> Here, we’ll run down what we know and what we don’t know about these variants. With much research yet to be done, there’s a lot of unanswered questions. But researchers are working quickly to address the most important unknowns. High on the list is whether the vaccines we already have will be effective against the variants. So far, it seems likely that they will be. Still, the virus is sending a clear message: with rampant transmission accelerating viral evolution, more variants will arise and we need to be prepared.</p><p> 在这里，我们将逐一介绍这些变体的已知知识和未知知识。尚未完成大量研究，因此有很多未解决的问题。但是研究人员正在迅速解决最重要的未知数。最重要的是我们已经拥有的疫苗是否会对变种有效。到目前为止，似乎很有可能。尽管如此，该病毒仍在发出明确的信息：随着猖transmission的传播加速病毒进化，将会出现更多的变种，我们需要做好准备。</p><p> With more data becoming available by the day, we’ll update this story with significant findings as they come along. Before we get to the data we have, a quick note on names: it’s problematic to identify diseases or infectious agents—in this case, virus variants—based on where they were identified. Such geographic associations risk creating stigma and may discourage reporting, so there is an  active discussion in the scientific community about how best to name the current variants. In the interim, it has become all too common to refer to these by their country of origin. We’ll try to avoid that as much as possible while making clear which variants we’re talking about.</p><p> 随着一天中越来越多的数据可用，我们将通过重要的发现来更新此故事。在获得数据之前，请先简短地说一下名称：在识别疾病或传染源（在这种情况下为病毒变体）的基础上，这是有问题的。这样的地理关联可能会产生污名，并可能阻止报告，因此科学界对如何最好地命名当前变体进行了积极的讨论。在此期间，按原籍国来提及这些名称已经变得非常普遍。我们会尽量避免这种情况，同时弄清楚我们在谈论哪些变体。</p><p>  Alternate names: 501Y.V1 and VOC 202012/01  Geographic association: United Kingdom  Number of countries reporting cases:  70  Increased transmissibility: Yes  Increased disease severity/mortality: A “realistic possibility”  Vaccine efficacy: Still effective</p><p>  备用名称：501Y.V1和VOC 202012/01地理协会：英国报告病例的国家数量：70传播率增加：是疾病严重度/死亡率增加：“现实的可能性”疫苗效力：仍然有效</p><p> In early December 2020, researchers and officials in the UK began warning of a new variant that seemed to be spreading abnormally fast while carrying an unusually large number of mutations—23. The first record of the variant in the UK stretched back to two samples taken from infected people on September 20 and September 21. In a matter of weeks, the variant began making up a larger and larger proportion of total cases there. Researchers quickly suspected the variant had evolved to become more transmissible—that is, it&#39;s able to spread more easily from person to person.</p><p> 2020年12月上旬，英国的研究人员和官员开始警告一种新变异，该变异看起来异常迅速地传播，同时携带了异常大量的突变-23。在英国，该变种的第一个记录可以追溯到9月20日和9月21日从感染者那里采集的两个样本。在短短的几周内，该变种开始在该地区的总病例中占越来越大的比例。研究人员很快就怀疑该变体已经进化为可传播的，也就是说，它能够在人与人之间更容易地传播。 </p><p>     Data analyses since December have supported that hypothesis, but researchers are still working out exactly how much more transmissible it is compared to earlier versions. In early January, UK researchers released preliminary results from a series of models that estimated the variant tacks on  an additional 0.36 to 0.68 onto SARS-CoV-2’s observed reproduction number. That means, on average, people infected with B.1.1.7 will go on to infect an  additional 0.36 to 0.68 people on top of how many they would have infected if they had an earlier version of the virus. More recent estimates have been roughly in this range, suggesting B.1.1.7 has around a  47 percent or  56 percent increase in transmission.</p><p>自去年12月以来的数据分析支持了这一假设，但研究人员仍在精确地计算出与早期版本相比其可传播性更高。 1月初，英国研究人员发布了一系列模型的初步结果，这些模型估计了SARS-CoV-2观测到的繁殖数量上的变种粘性增加了0.36至0.68。这意味着，平均而言，被B.1.1.7感染的人会继续感染另外0.36至0.68人，如果他们拥有较早版本的病毒，则将感染另外的人。最近的估计大致在此范围内，表明B.1.1.7的传输量增加了约47％或56％。</p><p> B.1.1.7 has now been detected in more than 60 countries beyond the UK, including the United States, where it has been found in  at least two dozen states. A  modeling study published by the US Centers for Disease Control and Prevention on January 15 estimated that it will become the predominant strain in the US in March.</p><p> 目前，在英国以外的60多个国家（包括美国）已检测到B.1.1.7，在至少两个州中都发现了B.1.1.7。美国疾病控制与预防中心1月15日发布的模型研究估计，它将在3月成为美国的主要毒株。</p><p>  Some of the mutations B.1.1.7 carries seem to help explain the virus’ newfound ability. The variant carries  23 mutations in all: 13 mutations that change the virus&#39; protein sequences (non-synonymous), four deletions, and six synonymous mutations. Of B.1.1.7’s mutations, eight occur in the virus’ spike protein, the now notorious club-like protein that juts out from the virus’ spherical particle. Spike is what the virus uses to latch onto and infect cells, which the protein accomplishes by binding a receptor on the outside of human cells called ACE2.</p><p>  B.1.1.7携带的某些突变似乎有助于解释该病毒的新发现能力。该变体总共带有23个突变：改变病毒的13个突变。蛋白质序列（非同义），四个缺失和六个同义突变。在B.1.1.7的突变中，有8个发生在病毒的刺突蛋白中，该蛋白现在是臭名昭著的棍状蛋白，从病毒的球形颗粒中突出出来。刺是病毒用来锁住并感染细胞的工具，该蛋白通过结合人类细胞外部称为ACE2的受体来完成。</p><p> So far, we know that  at least three of B.1.1.7’s eight spike mutations may be relevant to the variant’s boosted transmission. Chief among them is a mutation that changes one of the spike proteins’ critical amino acids—the amino acid at position 501 of spike’s protein sequence. Specifically, the mutation changes the amino acid at 501 from an asparagine (N) to a tyrosine (Y), so the mutation is written as N501Y. The 501 amino acid is critical because it lies within the area of spike that directly binds to ACE2—called the receptor binding domain (RBD)—and it is one of just six key contact residues in the RBD.  Lab experiments have suggested that changing from an N to a Y at 501 increases spike’s ability to bind ACE2, and  experiments in mice linked the mutation to increased infectiousness and disease.</p><p> 到目前为止，我们知道B.1.1.7的8个峰值突变中至少有3个可能与该变种的增强传播有关。其中最主要的是一种突变，它会改变刺突蛋白的关键氨基酸之一-刺突蛋白序列501位的氨基酸。具体而言，该突变将501处的氨基酸从天冬酰胺（N）变为酪氨酸（Y），因此该突变称为N501Y。 501氨基酸至关重要，因为它位于直接与ACE2结合的尖峰区域（称为受体结合域（RBD）），并且是RBD中仅有的六个关键接触残基之一。实验表明，在501时从N变为Y会增加刺突结合ACE2的能力，而小鼠实验表明该突变与传染性和疾病增加有关。</p><p> After N501Y, there’s P681H. The mutation at position 681—changing the amino acid from a proline (P) to a histidine (H)—falls near a unique furin cleavage site on SARS-CoV-2’s spike protein. For SARS-CoV-2 to successfully get into a cell after binding ACE2, the spike protein needs to be cleaved into its two subunits by enzymes. The split changes spike’s conformation and activates it, allowing it to fuse itself to the cell membrane and dump its contents into the now infected cell. In  animal studies, the furin cleavage site seemed to boost the virus’ ability to enter cells. Researchers suspect the new mutation may boost entry further.</p><p> N501Y之后是P681H。 681位突变将氨基酸从脯氨酸（P）变为组氨酸（H），位于SARS-CoV-2突突蛋白上唯一的弗林蛋白酶切割位点附近。为了使SARS-CoV-2在与ACE2结合后成功进入细胞，需要通过酶将刺突蛋白切割成两个亚基。分裂会改变刺突的构象并激活它，使其融合到细胞膜上，并将其内含物倾倒到现在被感染的细胞中。在动物研究中，弗林蛋白酶的裂解位点似乎增强了病毒进入细胞的能力。研究人员怀疑新的突变可能会进一步促进其进入。</p><p> The third spike mutation known to be significant is a deletion of six nucleotides in its genetic code, which leads to the loss of two amino acids at positions 69 and 70 in the spike protein. It’s unclear what this deletion does for the virus exactly, but it has arisen a number of times in different lineages, suggesting it  offers an advantage. For now, there is one clear consequence for researchers: the deletion messes up a diagnostic test for SARS-CoV-2. The test is a three-target RT-PCR test, meaning it works by detecting three snippets of the SARS-CoV-2 genome, including one in the gene that codes for spike. When this 69-70 deletion is present, the test will show up negative for the spike gene, but positive for the other two SARS-CoV-2 genetic sequences. This result is referred to as “ S gene dropout” and is now used to help identify infections caused by B.1.1.7.</p><p> 已知第三个明显的突触突变是其遗传密码中六个核苷酸的缺失，这导致突触蛋白中69和70位的两个氨基酸丢失。目前尚不清楚这种删除对病毒的确切作用，但它已经在不同谱系中出现了很多次，表明它具有优势。目前，对研究人员来说有一个明显的后果：删除该基因会破坏SARS-CoV-2的诊断测试。该测试是一种三目标RT-PCR测试，这意味着它可以通过检测SARS-CoV-2基因组的三个片段（包括编码尖峰的基因中的一个片段）来工作。如果存在此69-70缺失，则该测试将对刺突基因显示阴性，但对其他两个SARS-CoV-2遗传序列显示阳性。该结果被称为“ S基因缺失”，现在用于帮助鉴定由B.1.1.7引起的感染。</p><p>    These three mutations are the most notable in B.1.1.7 for now. There’s scant data on the other 20, but researchers are working swiftly to try to assess what each might do on their own or in combination with the others.</p><p>    这三个突变是目前B.1.1.7中最明显的。另外20个数据很少，但是研究人员正在迅速努力评估每个人自己或与其他人可能会做些什么。 </p><p>  When researchers first raised concern about B.1.1.7, all of that concern related to increased transmissibility. Preliminary evidence looking at infection outcomes did not suggest that B.1.1.7 was causing more severe disease or more deaths than other virus strains. Still, some saw little comfort in this, given that any increase in the total number of infections still leads to more severe cases and deaths in absolute numbers.</p><p>当研究人员首次提出对B.1.1.7的关注时，所有这些关注都与增加的透射率有关。有关感染结果的初步证据并不表明B.1.1.7导致比其他病毒株更严重的疾病或更多的死亡。不过，鉴于感染总数的任何增加仍然会导致更严重的病例和绝对死亡，因此有些人对此感到不安。</p><p> The situation took a darker turn January 21, when a UK government advisory group—NERVTAG—found  preliminary evidence that “there is a realistic possibility that infection with VOC B.1.1.7 is associated with an increased risk of death compared to infection with non-VOC viruses.”</p><p> 1月21日，情况发生了更加黑暗的转折，当时英国政府咨询小组NERVTAG发现了初步证据，“与未感染VOC B.1.1.7相比，VOC B.1.1.7感染与死亡风险增加存在现实的可能性。 -VOC病毒。”</p><p> So far, some experts are not yet convinced by the preliminary evidence presented and call for much more data before any conclusions are drawn. For one thing, the full data sets behind some of the analyses done so far have not been published, and some of them relied on comparing small numbers of deaths in people infected with B.1.1.7 with larger numbers of deaths in people infected with other strains. Some experts also wonder whether the calculated increase in deaths could simply be explained by overburdened hospitals rather than a deadlier variant.</p><p> 到目前为止，一些专家尚未对所提供的初步证据感到信服，并要求在得出任何结论之前提供更多数据。一方面，迄今为止尚未完成某些分析背后的全部数据集，其中一些数据依赖于将感染B.1.1.7的人中的少量死亡与感染B.1.1.7的人中的大量死亡进行比较。其他菌株。一些专家还想知道，计算得出的死亡人数增加是否只能由负担过重的医院来解释，而不是由更致命的形式来解释。</p><p>  With increased infectiousness and the possibility of being deadlier, a critical question raised by B.1.1.7 is whether or not the current vaccines we have—mRNA vaccines from Pfizer/BioNTech and Moderna—will work against the variant. So far, the answer appears to be yes.</p><p>  随着感染力的增强和致命性的提高，B.1.1.7提出了一个关键问题，即我们目前使用的疫苗（辉瑞/ BioNTech和Moderna的mRNA疫苗）是否可以对抗该变异。到目前为止，答案似乎是肯定的。</p><p> On January 19, researchers at Pfizer and BioNTech released  a non-peer reviewed study where they pitted antibody-laden blood from 16 people given their mRNA vaccine (BNT162b2) against a pseudovirus that carried B.1.1.7’s mutated spike protein. The researchers found that the vaccines’ antibodies were just as good at neutralizing the pseudovirus with B.1.1.7’s mutated spike protein as they were at neutralizing a pseudovirus with the spike protein from a reference SARS-CoV-2 virus. “These data… make it unlikely that the B.1.1.7 lineage will escape BNT162b2-mediated protection,” the researchers concluded.</p><p> 1月19日，辉瑞和BioNTech的研究人员发表了一项非同行评议的研究，他们从16人中提取了载有抗体的血液，注射了他们的mRNA疫苗（BNT162b2）对抗携带B.1.1.7突变的突突蛋白的假病毒。研究人员发现，疫苗的抗体在用B.1.1.7突变的刺突蛋白中和假病毒方面同样出色，在用参考SARS-CoV-2病毒的刺突蛋白中和假病毒方面同样出色。研究人员总结说：“这些数据……使B.1.1.7血统不太可能摆脱BNT162b2介导的保护。”</p><p> Likewise, on January 25, Moderna released its own  non-peer reviewed study, which was similar in design. They tested the antibodies from eight people given their mRNA vaccine against a pseudovirus bearing B.1.1.7’s mutated spike protein. Again, the antibodies neutralized the pseudovirus at levels comparable to those seen with a pseudovirus carrying a reference spike protein.</p><p> 同样，1月25日，Moderna发布了自己的非同行评审研究，该研究在设计上相似。他们测试了八名接受过mRNA疫苗接种的人的抗体，以对抗带有B.1.1.7突变突突蛋白的假病毒。抗体再次中和假病毒，其水平与携带参考刺突蛋白的假病毒所见水平相当。</p><p> Yet  another similar study, led by researchers at Columbia University and released January 26, found the same results. Antibodies from 12 people who received Moderna’s vaccine and 10 people who received Pfizer’s vaccine were able to neutralize a pseudovirus containing B.1.1.7’s mutated spike protein, with only a modest drop in potency compared with neutralization of a pseudovirus carrying a reference spike protein.</p><p> 由哥伦比亚大学的研究人员领导并于1月26日发布的另一项类似研究发现了相同的结果。来自接受Moderna疫苗的12个人和接受辉瑞疫苗的10个人的抗体能够中和含有B.1.1.7突变的刺突蛋白的假病毒，与中和携带参考刺突蛋白的假病毒相比，其效力仅适度下降。 </p></div><div id="story_share_this"><div class="sharethis-inline-share-buttons"></div></div><div class="text-break sotry_link page_narrow"><a target="_blank" href="https://arstechnica.com/science/2021/01/coronavirus-variants-what-they-do-and-how-worried-you-should-be/">https://arstechnica.com/science/2021/01/coronavirus-variants-what-they-do-and-how-worried-you-should-be/</a></div><div class="story_tags page_narrow"><button type="button" class="btn btn-light my_tag"><a href="/tag/冠状病毒/">#冠状病毒</a></button><button type="button" class="btn btn-light my_tag"><a href="/tag/病毒/">#病毒</a></button><button type="button" class="btn btn-light my_tag"><a href="/tag/变种/">#变种</a></button><button type="button" class="btn btn-light my_tag"><a href="/tag/variants/">#variants</a></button></div></div><div class="my_movie_list_item shadow p-3 mb-5 bg-white rounded"><button type="button" class="btn btn-link my_tag"><a href="/tag/web2.0/">#web2.0</a></button><button type="button" class="btn btn-link my_tag"><a href="/tag/google/">#google</a></button><button type="button" class="btn btn-link my_tag"><a href="/tag/设计/">#设计</a></button><button type="button" class="btn btn-link my_tag"><a href="/tag/创意/">#创意</a></button><button type="button" class="btn btn-link my_tag"><a href="/tag/摄影/">#摄影</a></button><button type="button" class="btn btn-link my_tag"><a href="/tag/游戏/">#游戏</a></button><button type="button" class="btn btn-link my_tag"><a href="/tag/图片/">#图片</a></button><button type="button" class="btn btn-link my_tag"><a href="/tag/软件/">#软件</a></button><button type="button" class="btn btn-link my_tag"><a href="/tag/视频/">#视频</a></button><button type="button" class="btn btn-link my_tag"><a href="/tag/手机/">#手机</a></button><button type="button" class="btn btn-link my_tag"><a href="/tag/广告/">#广告</a></button><button type="button" class="btn btn-link my_tag"><a href="/tag/iphone/">#iphone</a></button><button type="button" class="btn btn-link my_tag"><a href="/tag/网站/">#网站</a></button><button type="button" class="btn btn-link my_tag"><a href="/tag/免费/">#免费</a></button><button type="button" class="btn btn-link my_tag"><a href="/tag/下载/">#下载</a></button><button type="button" class="btn btn-link my_tag"><a href="/tag/windows/">#windows</a></button><button type="button" class="btn btn-link my_tag"><a href="/tag/微软/">#微软</a></button><button type="button" class="btn btn-link my_tag"><a href="/tag/苹果/">#苹果</a></button><button type="button" class="btn btn-link my_tag"><a href="/tag/apple/">#apple</a></button><button type="button" class="btn btn-link my_tag"><a href="/tag/blog/">#blog</a></button><button type="button" class="btn btn-link my_tag"><a href="/tag/firefox/">#firefox</a></button><button type="button" class="btn btn-link my_tag"><a href="/tag/音乐/">#音乐</a></button><button type="button" class="btn btn-link my_tag"><a href="/tag/博客/">#博客</a></button><button type="button" class="btn btn-link my_tag"><a href="/tag/wordpress/">#wordpress</a></button><button type="button" class="btn btn-link my_tag"><a href="/tag/恶搞/">#恶搞</a></button><button type="button" class="btn btn-link my_tag"><a href="/tag/qq/">#qq</a></button><button type="button" class="btn btn-link my_tag"><a href="/tag/艺术/">#艺术</a></button><button type="button" class="btn btn-link my_tag"><a href="/tag/web/">#web</a></button><button type="button" class="btn btn-link my_tag"><a href="/tag/工具/">#工具</a></button><button type="button" class="btn btn-link my_tag"><a href="/tag/分享/">#分享</a></button></div></div></div><div id="my_footer"><div class=""><a href="/tags/">tags</a> <a href="/users/">users</a></div>&copy; 2020 diglog.com </div></div></body></html>